HYDRALAZINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C8H8N4
Molecular Weight	160.1759
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NNC1=C2C=CC=CC2=CN=N1

InChI

InChIKey=RPTUSVTUFVMDQK-UHFFFAOYSA-N

InChI=1S/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12)

HIDE SMILES / InChI

Description
Sources: http://www.drugbank.ca/drugs/DB01275
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/cdi/hydralazine.html

Hydralazine is a direct-acting vasodilator that is used as an antihypertensive agent. Hydralazine works by relaxing blood vessels (arterioles more than venules) and increasing the supply of blood and oxygen to the heart while reducing its workload. It also functions as an antioxidant. It inhibits membrane-bound enzymes that form reactive oxygen species, such as superoxides. Excessive superoxide counteracts NO-induced vasodilation. Hydralazine is used for the treatment of essential hypertension, alone or as an adjunct. Also for the management of severe hypertension when the drug cannot be given orally or when blood pressure must be lowered immediately, congestive heart failure (in combination with cardiac glycosides and diuretics and/or with isosorbide dinitrate), and hypertension secondary to pre-eclampsia/eclampsia.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Amine oxidase, copper containing 9 Target ID: CHEMBL3437 Sources: http://www.drugbank.ca/drugs/DB01275	Inhibitor 8504
uterine smooth muscle contraction 3 Target ID: GO:0070471 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3354891	Inhibitor 8504		400.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 575 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/040136s005lbl.pdf	Primary		Approved 8583	Hydralazine Hydrochloride Approved Use Severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower blood pressure. Launch Date 1985

C_max

Value	Dose	Co-administered	Analyte	Population
3 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/6653641	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: HYDRALAZINE	HYDRALAZINE	HYDRALAZINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
407 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/6653641	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: HYDRALAZINE	HYDRALAZINE	HYDRALAZINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
2 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/6653641	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: HYDRALAZINE	HYDRALAZINE	HYDRALAZINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
13% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf			HYDRALAZINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
2000 mg single, oral Overdose Dose: 2000 mg Route: oral Route: single Dose: 2000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/1536497	unhealthy, 27 Health Status: unhealthy Age Group: 27 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/1536497	Disc. AE: Tachycardia... AEs leading to discontinuation/dose reduction: Tachycardia Sources: https://pubmed.ncbi.nlm.nih.gov/1536497
750 mg single, oral Overdose Dose: 750 mg Route: oral Route: single Dose: 750 mg Sources: https://pubmed.ncbi.nlm.nih.gov/30821162	unhealthy, 38 Health Status: unhealthy Age Group: 38 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/30821162	Disc. AE: Lethargy, Hypotension... AEs leading to discontinuation/dose reduction: Lethargy Hypotension Tachycardia Chest pain Sources: https://pubmed.ncbi.nlm.nih.gov/30821162
200 mg 1 times / day multiple, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://www.medicines.org.uk/emc/product/4527	unhealthy Health Status: unhealthy Sources: https://www.medicines.org.uk/emc/product/4527	Disc. AE: Skin rash, Febrile reaction... AEs leading to discontinuation/dose reduction: Skin rash (rare) Febrile reaction (rare) Sources: https://www.medicines.org.uk/emc/product/4527
300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf	Disc. AE: Systemic lupus erythematosus synd, Glomerulonephritis... AEs leading to discontinuation/dose reduction: Systemic lupus erythematosus synd Glomerulonephritis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf	Disc. AE: Angina pectoris, Myocardial infarction... AEs leading to discontinuation/dose reduction: Angina pectoris Myocardial infarction Peripheral neuritis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
40 mg single, intravenous Recommended Dose: 40 mg Route: intravenous Route: single Dose: 40 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/040136s005lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/040136s005lbl.pdf	Disc. AE: Systemic lupus erythematosus synd, Glomerulonephritis... AEs leading to discontinuation/dose reduction: Systemic lupus erythematosus synd Glomerulonephritis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/040136s005lbl.pdf

AEs

AE	Significance	Dose	Population
Tachycardia	Disc. AE	2000 mg single, oral Overdose Dose: 2000 mg Route: oral Route: single Dose: 2000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/1536497	unhealthy, 27 Health Status: unhealthy Age Group: 27 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/1536497
Chest pain	Disc. AE	750 mg single, oral Overdose Dose: 750 mg Route: oral Route: single Dose: 750 mg Sources: https://pubmed.ncbi.nlm.nih.gov/30821162	unhealthy, 38 Health Status: unhealthy Age Group: 38 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/30821162
Hypotension	Disc. AE	750 mg single, oral Overdose Dose: 750 mg Route: oral Route: single Dose: 750 mg Sources: https://pubmed.ncbi.nlm.nih.gov/30821162	unhealthy, 38 Health Status: unhealthy Age Group: 38 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/30821162
Lethargy	Disc. AE	750 mg single, oral Overdose Dose: 750 mg Route: oral Route: single Dose: 750 mg Sources: https://pubmed.ncbi.nlm.nih.gov/30821162	unhealthy, 38 Health Status: unhealthy Age Group: 38 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/30821162
Tachycardia	Disc. AE	750 mg single, oral Overdose Dose: 750 mg Route: oral Route: single Dose: 750 mg Sources: https://pubmed.ncbi.nlm.nih.gov/30821162	unhealthy, 38 Health Status: unhealthy Age Group: 38 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/30821162
Febrile reaction	rare Disc. AE	200 mg 1 times / day multiple, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://www.medicines.org.uk/emc/product/4527	unhealthy Health Status: unhealthy Sources: https://www.medicines.org.uk/emc/product/4527
Skin rash	rare Disc. AE	200 mg 1 times / day multiple, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://www.medicines.org.uk/emc/product/4527	unhealthy Health Status: unhealthy Sources: https://www.medicines.org.uk/emc/product/4527
Glomerulonephritis	Disc. AE	300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
Systemic lupus erythematosus synd	Disc. AE	300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
Angina pectoris	Disc. AE	300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
Myocardial infarction	Disc. AE	300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
Peripheral neuritis	Disc. AE	300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
Glomerulonephritis	Disc. AE	40 mg single, intravenous Recommended Dose: 40 mg Route: intravenous Route: single Dose: 40 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/040136s005lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/040136s005lbl.pdf
Systemic lupus erythematosus synd	Disc. AE	40 mg single, intravenous Recommended Dose: 40 mg Route: intravenous Route: single Dose: 40 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/040136s005lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/040136s005lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2B6 926 CYP2C8 1057 CYP2C19 2057 CYP3A 227 aldehyde oxidase 5 CYP2A6 879 BSEP 550 OCT1 620 OATP1B1 1079 OATP1B3 961

Drug as perpetrator

Target	Modality	Activity
BSEP 554	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/22961681/	no [IC50 >1000 uM]
CYP2A6 911	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/22522748/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNzIxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDI3NjgzMiJ9fQ%3D%3D	no
CYP2C19 2141	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/30448524/	unlikely
CYP2C8 1117	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/30448524/	unlikely
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/30448524/	unlikely
OCT1 656	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/18788725/	unlikely
CYP3A4 2633	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/9384469/, https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000086544	yes [IC50 197 uM]
aldehyde oxidase 5	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/30448524/, https://pubmed.ncbi.nlm.nih.gov/22522748/	yes [Ki 83 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/30448524/	yes
CYP2B6 1160	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/30448524/	yes
CYP2D6 2546	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/30448524/	yes
CYP3A 317	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/30448524/	yes
OATP1B1 1095	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23571415/	yes
OATP1B3 970	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23571415/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMjc2ODMyIn19

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:5775	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5775
ChemicalBook	CB1855362	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1855362
eMolecules	1978120	https://www.emolecules.com/cgi-bin/more?vid=1978120
eMolecules	975874	https://www.emolecules.com/cgi-bin/more?vid=975874
MolPort	MolPort-000-876-738	https://www.molport.com/shop/molecule-link/MolPort-000-876-738
ZINC	ZINC000012360535	http://zinc15.docking.org/substances/ZINC000012360535

PubMed

Title	Date	PubMed
Diesel exhaust induced pulmonary and cardiovascular impairment: the role of hypertension intervention.	2013-04-15	23415681
Acrolein and chloroacetaldehyde: an examination of the cell and cell-free biomarkers of toxicity.	2013-02-25	23220588
Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.	2012-05	22318512
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.	2011-07-14	21599003
Antiatherogenic effect of bisvanillyl-hydralazone, a new hydralazine derivative with antioxidant, carbonyl scavenger, and antiapoptotic properties.	2011-06	21043830
Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway.	2011-05	21289285
HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats.	2010-09	20679181
Hydralazine for essential hypertension.	2010-08-04	20687078
Chitosan nanoparticle-based neuronal membrane sealing and neuroprotection following acrolein-induced cell injury.	2010-01-29	20205817
D-penicillamine-induced autoimmunity: relationship to macrophage activation.	2009-09	19575532
Resveratrol attenuates angiotensin II-induced interleukin-6 expression and perivascular fibrosis.	2009-06	19373235
Administration of angiotensin II, but not catecholamines, induces accumulation of lipids in the rat heart.	2009-02-14	19109942
4-Hydrazino-2-(methyl-sulfan-yl)-pyrimidine.	2009-01-31	21582010
Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation.	2009-01-01	19109157
"Pulse" treatment with high-dose angiotensin blocker reverses renal arteriolar hypertrophy and regresses hypertension.	2009-01	19047581
Hydralazine-induced cholestatic hepatitis.	2008-12-19	19092641
Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition.	2008-12	18493746
The prince and the pauper. A tale of anticancer targeted agents.	2008-10-23	18947424
Simultaneous posterior ischemic optic neuropathy, cerebral border zone infarction, and spinal cord infarction after correction of malignant hypertension.	2008-09	18769283
Hypertension induces somatic cellular senescence in rats and humans by induction of cell cycle inhibitor p16INK4a.	2008-07	18504326
Beneficial effects of the Rho kinase inhibitor Y27632 in murine puromycin aminonucleoside nephrosis.	2008	18367845
Persistent hypertension and progressive renal injury induced by salt overload after short term nitric oxide inhibition.	2007-12	18209918
D-Penicillamine-induced ANCA-associated crescentic glomerulonephritis in Wilson disease.	2007-11	17954295
A randomised comparison of hydralazine and mini-bolus diazoxide for hypertensive emergencies in pregnancy: the PIVOT trial.	2007-08	17627681
Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial.	2007-04-03	17372175
The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study.	2007-02-26	17324262
Role of connective tissue growth factor in vascular and renal damage associated with hypertension in rats. Interactions with angiotensin II.	2006-12	17318787
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.	1991-08-01	2057035
Renal arteriolar diameters in spontaneously hypertensive rats. Vascular cast study.	1991-07	1860704
Effects of hydralazine and increased cardiac output on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism.	1991-03	1899825
Cardiotoxicity of hydralazine and minoxidil in the rat. Influence of age.	1991-02	2047568
Hemodynamic effects of adenosine agonists in the conscious spontaneously hypertensive rat.	1990-09	2203898
Acute cocaine toxicity: antagonism by agents interacting with adrenoceptors.	1990-06	2162541
Prevention of arterial disease in experimental renal hypertension.	1990-04	1971779
Changes of atrial natriuretic peptide and its messenger RNA with development and regression of cardiac hypertrophy in renovascular hypertensive rats.	1990-01	2136812
Myocardial ischemia during isoflurane anesthesia: the effect of substituting halothane.	1989-06	2729620
Hydralazine-induced cholestatic jaundice following liver transplantation.	1989-01	2643228
Isolated minimal change nephropathy associated with diclofenac.	1987-07-18	3115369
Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans.	1987-05	2953239
Inhibition of sympathoadrenal activity by atrial natriuretic factor in dogs.	1987-04	2951327
Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat.	1986-06	3011863
Drug-associated glomerulopathies.	1986	2940667
Comparative study of endralazine and hydralazine for the treatment of hypertension uncontrolled by a beta-blocker and diuretic.	1986	2873966
Clinical pharmacology and therapeutic role of prazosin and related alpha-adrenoceptor antagonists.	1986	2872958
Therapeutic implications of hypertension-induced glomerular injury. Comparison of enalapril and a combination of hydralazine, reserpine, and hydrochlorothiazide in an experimental model.	1985-09-27	2996345
Suppression of ventricular arrhythmias after coronary artery ligation by pinacidil, a vasodilator drug.	1985-09-01	2413295
Acute hemodynamic effects of pinacidil and hydralazine in essential hypertension.	1985-03	2857601
Effects of chronic treatment with captopril (SQ 14,225), an orally active inhibitor of angiotensin I-converting enzyme, in spontaneously hypertensive rats.	1979-04	231700
Immunological side-effects of antihypertensive drugs.	1979	288303
Clinical consequences of polymorphic acetylation of basic drugs.	1977-09	19187

Patents

Sample Use Guides

In Vivo Use Guide

Initial dose: 10 mg orally 4 times a day for the first 2 to 4 days. Increase to 25 mg orally 4 times a day for the balance of the first week. For the second and subsequent weeks, increase dosage to 50 mg orally 4 times a day.

Route of Administration: Oral

In Vitro Use Guide

Hydralazine (0.03-10 mmol.L(-1)) inhibited the activities of both PKA and PKG with IC50 of 1.2 and 2.5 mmol.L(-1), respectively

Name

Type

Language

HIDRAL

Preferred Name

English

HYDRALAZINE

Official Name

English

1-HYDRAZINOPHTHALAZINE

Systematic Name

English

HYDRALAZINE [MI]

Common Name

English

hydralazine [INN]

Common Name

English

DIHYDRALAZINE SULFATE, HYDRATED IMPURITY B [EP IMPURITY]

Common Name

English

Hydralazine [WHO-DD]

Common Name

English

NSC-126699

Code

English

HYDRALAZINE [IARC]

Common Name

English

HYDRALAZINE [VANDF]

Common Name

English

PHTHALAZINE, 1-HYDRAZINO-

Systematic Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

334611